

Fujifilm Biotechnologies announces biomanufacturing and process development expansion in UK

12 February 2026 | News

Funded through a total investment of approximately £400 million



Fujifilm Biotechnologies, a world leading contract development and manufacturing organisation (CDMO) for biologics, vaccines, and advanced therapies, recently announced the grand opening of its expanded site in Teesside, UK.

The significantly expanded presence, funded through a total investment of approximately £400 million from Fujifilm Corporation, Japan, includes the opening of the largest single-use biopharmaceutical CDMO facility in the UK, located at the existing Fujifilm Biotechnologies site.

The UK expansion represents the newest addition to Fujifilm Biotechnologies' global manufacturing network and introduces 2,000 L and 5,000 L single-use bioreactors with a total capacity up to 19,000 L to provide small- and mid-scale antibody manufacturing, with the flexibility to expand to support customer programmes as needed. The 110,000 sq. ft. manufacturing facility will be operational in the first half of 2026.

In parallel, the opening of the Bioprocess Innovation Centre UK (BIC UK), delivers a state-of-the art laboratory for both high-throughput, and continuous process development capabilities, and will operate as a global centre of excellence for biomanufacturing innovation and process development. The over 102,200 sq. ft. facility doubles the campus' existing lab footprint and complements the sites' expanded Good Manufacturing Practice (GMP) manufacturing capabilities.